Shock Wave Lithotripsy in Pediatric Stone Disease: A 15-Year Single-Center Experience with 2 Types of Lithotripters.


Journal

Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373

Informations de publication

Date de publication:
2022
Historique:
received: 31 01 2021
accepted: 12 01 2022
pubmed: 17 2 2022
medline: 15 12 2022
entrez: 16 2 2022
Statut: ppublish

Résumé

We report our experience with pediatric shock wave lithotripsy (SWL) using two types of lithotripters: Dornier HM3 (HM3) and Dornier Lithotripter SII (DLS). We retrospectively reviewed the charts of children who underwent SWL between 2002 and 2016. Patients were divided into two groups based on the type of the lithotripter: during 2002-2009, we used the electrohydraulic HM3 lithotripter which was replaced in 2009 with the DLS electromagnetic lithotripter. Clinical and perioperative parameters were compared. Our cohort included 107 children who underwent SWL. Average age was 11.5 ± 5.1 years. Average stone size was 10.6 ± 4.9 mm. HM3 was used in 38% of children and DLS2 in 62% (n = 41 and 66, respectively). There were no significant differences in age, gender, stone size, or location between the groups. The total SFR did not differ statistically between HM3 and DLS (83% vs. 74%, p = 0.35). SFR after one SWL was higher with the HM3 (78% vs. 62%, p = 0.093). Re-treatment rate was 22% and 17% (HM3 vs. DLS, p = 0.61). Complication rates were low, with renal colic being the most common (HM3 10%, DLS 20%, NS). SWL in the pediatric population using the DLS showed good results with low complication rates that are equivalent to the gold standard HM3.

Identifiants

pubmed: 35172318
pii: 000522079
doi: 10.1159/000522079
pmc: PMC9811415
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1260-1264

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Références

BMC Urol. 2019 Oct 23;19(1):98
pubmed: 31640693
J Urol. 2001 Nov;166(5):1862-4
pubmed: 11586249
J Urol. 2002 May;167(5):2164-6
pubmed: 11956471
Urol Res. 2012 Oct;40(5):599-603
pubmed: 22580634
BJU Int. 2009 Jan;103(1):81-4
pubmed: 18727616
J Urol. 2009 Oct;182(4 Suppl):1835-9
pubmed: 19692011
J Pediatr Urol. 2006 Oct;2(5):459-63
pubmed: 18947656
J Endourol. 2017 Feb;31(2):180-184
pubmed: 27899041
J Urol. 2008 Oct;180(4 Suppl):1865-8
pubmed: 18721967
Arch Ital Urol Androl. 2018 Sep 30;90(3):169-171
pubmed: 30362681
Korean J Urol. 2013 Jul;54(7):460-6
pubmed: 23878689
BJU Int. 2000 Nov;86(7):851-6
pubmed: 11069413
J Urol. 2010 Oct;184(4 Suppl):1804-9
pubmed: 20728112
Urolithiasis. 2015 Jun;43(3):199-206
pubmed: 25721456
J Pediatr Urol. 2019 Aug;15(4):391.e1-391.e7
pubmed: 31182399
J Pediatr Urol. 2007 Jun;3(3):235-8
pubmed: 18947742
J Endourol. 2009 Feb;23(2):223-7
pubmed: 19196061
J Urol. 2007 Sep;178(3 Pt 1):912-5
pubmed: 17632139
Pediatr Surg Int. 2008 May;24(5):579-81
pubmed: 18365216
BJU Int. 2020 Mar;125(3):457-466
pubmed: 31663246
Transl Pediatr. 2015 Jan;4(1):33-5
pubmed: 26835357
Urology. 2003 Jan;61(1):212-5; discussion 215
pubmed: 12559298
J Urol. 2005 Jun;173(6):2013-6
pubmed: 15879807
Urology. 2013 Apr;81(4):880-4
pubmed: 23395121
J Pediatr Urol. 2020 Oct;16(5):612-624
pubmed: 32739360
Eur Urol. 2011 Apr;59(4):637-44
pubmed: 21296481
J Endourol. 2017 May;31(5):510-516
pubmed: 28355100

Auteurs

Ariel Zisman (A)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Akram Assadi (A)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Oleg Goldin (O)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Kamil Malshy (K)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Omri Nativ (O)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Shimon Meretyk (S)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Gilad E Amiel (GE)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Michael Mullerad (M)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Pinhas M Livne (PM)

Urology Department, Rambam Health Care Campus, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH